Replimune Group Inc (REPL)

$8.39 -0.25 (-2.89%)
Market Cap 713.43M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 1,311,900
Avg Vol 1,381,928
Day's Range N/A - N/A
Shares Out 82.57M
Stochastic %K 73%
Beta 0.73
Analysts Strong Sell
Price Target $12.86

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
UgoGreg
UgoGreg Feb. 21 at 5:24 PM
$REPL https://youtu.be/ygBN8MilTyc
0 · Reply
Biotech_Beast
Biotech_Beast Feb. 21 at 12:16 PM
$REPL Hoping the drug is approved this time around so they can raise funds to continue working on RP1 and RP2, promising agents. $IOVA should note potential approval of competition on April 10. https://seekingalpha.com/article/4873142-replimune-multiple-shots-on-goal-but-a-high-risk-binary-approaches
1 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 3:08 PM
$REPL
0 · Reply
BigProfitz
BigProfitz Feb. 19 at 8:23 PM
$REPL Big uptick...Let's Go!!
0 · Reply
SaTwits
SaTwits Feb. 19 at 3:12 PM
$VNDA $RCKT $GRCE $MNKD $REPL @GikozTwits
2 · Reply
Stock_Catcher
Stock_Catcher Feb. 19 at 2:11 AM
Treasure Thursday Watchlist Pt. 7 $REPL $SLS $SLV $NAK $AUUD Let's Find Gems Tomorrow
0 · Reply
MysticChartReaderIQ69
MysticChartReaderIQ69 Feb. 18 at 6:22 PM
$REPL nice little bull trap
0 · Reply
TradingThesis
TradingThesis Feb. 18 at 4:02 PM
$REPL Replimune develops oncolytic immunotherapies. Clinical data drives valuation swings. Cash runway supports development.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 18 at 3:20 PM
$REPL wowza
0 · Reply
Quantumup
Quantumup Feb. 18 at 2:54 PM
Cantor reiterated Top Pick $IDYA at an Overweight rating heading into Ideaya's topline PFS readout from the Ph2/3 OptimUM-02 trial in 1L MUM (metastatic uveal melanoma) slated for the last week of March. $IMCR $REPL $BMY $PFE GILD AMGN GSK MRK DCTH Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2024134420320374998?s=20
0 · Reply
Latest News on REPL
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 20 days ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 7:15 PM EST - 5 weeks ago

Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 2 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 3 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID NTLA SOC

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 3 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 4 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 4 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 21, 2025, 7:40 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 5 months ago

Replimune Provides Update Following Type A Meeting with FDA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 13, 2025, 10:10 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 6 months ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 6 months ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Replimune Announces Type A Meeting Scheduled with FDA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 6 months ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 7 months ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 7 months ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 7 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 7 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 7 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 7 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 7 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 7 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 8 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 9 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 9 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 9 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 9 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 10 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

UgoGreg
UgoGreg Feb. 21 at 5:24 PM
$REPL https://youtu.be/ygBN8MilTyc
0 · Reply
Biotech_Beast
Biotech_Beast Feb. 21 at 12:16 PM
$REPL Hoping the drug is approved this time around so they can raise funds to continue working on RP1 and RP2, promising agents. $IOVA should note potential approval of competition on April 10. https://seekingalpha.com/article/4873142-replimune-multiple-shots-on-goal-but-a-high-risk-binary-approaches
1 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 3:08 PM
$REPL
0 · Reply
BigProfitz
BigProfitz Feb. 19 at 8:23 PM
$REPL Big uptick...Let's Go!!
0 · Reply
SaTwits
SaTwits Feb. 19 at 3:12 PM
$VNDA $RCKT $GRCE $MNKD $REPL @GikozTwits
2 · Reply
Stock_Catcher
Stock_Catcher Feb. 19 at 2:11 AM
Treasure Thursday Watchlist Pt. 7 $REPL $SLS $SLV $NAK $AUUD Let's Find Gems Tomorrow
0 · Reply
MysticChartReaderIQ69
MysticChartReaderIQ69 Feb. 18 at 6:22 PM
$REPL nice little bull trap
0 · Reply
TradingThesis
TradingThesis Feb. 18 at 4:02 PM
$REPL Replimune develops oncolytic immunotherapies. Clinical data drives valuation swings. Cash runway supports development.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 18 at 3:20 PM
$REPL wowza
0 · Reply
Quantumup
Quantumup Feb. 18 at 2:54 PM
Cantor reiterated Top Pick $IDYA at an Overweight rating heading into Ideaya's topline PFS readout from the Ph2/3 OptimUM-02 trial in 1L MUM (metastatic uveal melanoma) slated for the last week of March. $IMCR $REPL $BMY $PFE GILD AMGN GSK MRK DCTH Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2024134420320374998?s=20
0 · Reply
Dorps332
Dorps332 Feb. 18 at 2:42 PM
$IOVA volume on $REPL is already ahead of us at open?
0 · Reply
Dorps332
Dorps332 Feb. 17 at 8:27 PM
$REPL looks like it’s Our day to get smacked to hell
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 14 at 3:53 PM
Our records indicate the FDA has not approved 1 new drug/therapy from non-Big Pharma year-to-date (excluding devices). Attached is a list of all the PDUFA dates YTD & the FDA response. Next 5 up to become 1st time commercial-stage bios (per our records) include $ALDX (3/16/26) $RCKT (3/28/26) $DNLI (4/5/26) $REPL (oncology 4/10/26) $GRCE (4/23/26) Our list may not be complete. This is not investment advice.
7 · Reply
Dorps332
Dorps332 Feb. 13 at 5:45 PM
$REPL back over $9 would be great
0 · Reply
ignoreo
ignoreo Feb. 13 at 1:15 AM
$MRNA $REPL $QURE $CAPR $RGNX its strange to think about but by the time vinay prasad's conquest is over, he will have killed more americans than hitler. and it wont even be close
1 · Reply
JFais
JFais Feb. 11 at 1:11 PM
$MRNA (NP) FDA unpredictability continues with RTF for mRNA-1010 seasonal influenza vaccine despite crossing its T's and dotting the i's: -Used Priority Review Voucher -Followed FDA's April 2024 guidance on standard dose comparator -Included data from separate phase 3 comparing vs high-dose Casualties abound $ATRA $REPL $RGNX $QURE And the fallout continues to push investors away from biotech & discourage innovation @DrMakaryFDA @VPrasadMDMPH
0 · Reply
GeneralAdam
GeneralAdam Feb. 10 at 9:32 AM
$REPL wtf?
0 · Reply
Evagaminska
Evagaminska Feb. 9 at 10:08 PM
$RGNX I bet Prasad is the one who screwing patients as he single-handedly is killing small&medium size biotechs. Look at $REPL $SRPT $CAPR and many others all while if able push big pharma treatments $HIMS is American company trying to make cheaper diagnostics in cancer, blood disorders and also have cheap weight loss options while big pharma until recently charged big money FDA and SEC siding with NVO Lawsuit doesn’t mean there will be a trial and that NVO will win but the power of gov with the help from Wall Street and media destroys competition especially now when TrumpRx opened How is this even legal TrumpRx? Trump after 6 bankruptcies doesn’t own buildings his name was removed in many so to boost his narcissistic ego the gov names everything with his name making the illusion people love this guy?In 2024 some voters did as they hoped his experience would make his presidency better but unfortunately it didn’t He joined the swamp and profits from being POTUS Scammer
3 · Reply
Evagaminska
Evagaminska Feb. 6 at 10:33 PM
$PLSE This is possibly a good news for everyone involved patients and investors but if you follow closely FDA under Trump you can notice they’re killing small biotech innovation and do everything to protect and approve big pharma treatments Clown Prasad gave CRL to $REPL that followed all steps of FDA yet admin changed he was new to the job and was giving CRL left and right with idiot Makary running to media REPL had trx for skin cancer got CRL and 2 months later FDA approved big pharma trx for same cancer They’re also”killing”rare diseases biotech like $CAPR or $SRPT putting multiple roadblocks but approve weight loss trx with long term severe side effects or freaking vaccines Criminal mafia
3 · Reply
JFais
JFais Feb. 4 at 5:00 PM
$REPL wants to hit the ground running in April with RP1 and has ambitious LT expansion plans in place for other solid tumors @stevenvig Key question as always, will the FDA's @DrMakaryFDA and team support innovation or withhold another promising treatment from patients? $QURE
0 · Reply
FiftyTwoWeekHighs
FiftyTwoWeekHighs Feb. 4 at 4:02 PM
$REPL is a software company (Repligen Corporation) providing bioprocessing technologies; its growth is tied to biopharma manufacturing capacity expansion, which is currently slowing.
0 · Reply
erevnon
erevnon Feb. 4 at 2:48 PM
Wedbush maintains Replimune Group $REPL at Outperform and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply